
Early results from major clinical trial show healthy lifestyle slows cognitive decline
Her focus on exercise is light-years away from where Jones, 66, of Aurora, Illinois, was just a few years ago. She had prediabetes, and her cholesterol and blood pressure levels were inching up.
She was totally sedentary after falling into deep depression. 'I was in bed. I didn't care at all. I was just spiraling,' Jones said.
She was probably also destined to lose her ability to think clearly.
Jones' mother and grandmother died of vascular dementia, a condition that occurs when the body can't pump enough blood to the brain. Other family members had the disease, too.
'Watching two generations suffer made me determined to break the cycle for myself,' Jones said. 'I'm not that person anymore.'
Four years ago, Jones joined a major clinical trial, called U.S. POINTER, that aimed to figure out how older adults at high risk for dementia can stay healthier longer.
Half of the more than 2,000 participants were given advice on a healthy lifestyle, including diet and exercise. The other half was thrust into a structured, team-based program that gave participants goals to transform their lifestyles. The program included meeting with experts and other participants regularly, as well as brain exercises and aerobics classes. Participants were instructed to follow the MIND diet, which trades processed foods for whole grains, fruits, leafy greens and other vegetables.
The researchers evaluated cognitive function by measuring memory, the ability to focus while juggling multiple tasks, and how quickly people interpreted and responded to information.
After two years, both groups showed progress. But people in the structured group saw greater benefits.
'Our conservative estimate shows that, relative to the self-guided group, the structured group performed at a level comparable to adults who were one to two years younger in age,' said Laura Baker, lead researcher and a gerontology professor at Wake Forest University School of Medicine and Advocate Health in Winston-Salem, North Carolina.
'This is what's giving folks additional resilience against cognitive decline,' she said.
Greater support and accountability in the structured group were key benefits.
'We're going to tell you what to do, but we're also going to help you get there, and we're going to work with you as a partner to meet you where you are,' Baker said during a news briefing about the findings Monday at the Alzheimer's Association International Conference in Toronto.
The research, published simultaneously in the Journal of the American Medical Association, is the first large-scale randomized controlled trial to show that organized, sustainable lifestyle interventions can have a measurable impact on brain health.
It's an important finding as the nation is on a path to double the number of people living with dementia by 2060. About 10% of Americans over age 65 have been diagnosed with dementia, according to the Centers for Disease Control and Prevention. Nearly 7 million people in the U.S. have Alzheimer's, the most common type of dementia.
While some drugs may slow how quickly dementia develops, there is no cure.
'Some people are scared, thinking there's nothing you can do' to ward off dementia, said Dr. Richard Isaacson, a neurologist and researcher at the Institute for Neurodegenerative Diseases in Florida.
We're not powerless in the fight against cognitive decline.
Dr. Richard Isaacson
The new findings, he said, show that 'we're not powerless in the fight against cognitive decline and Alzheimer's disease.' Isaacson, who formerly directed the Alzheimer's Prevention Clinic at NewYork-Presbyterian/Weill Cornell Medical Center, was not involved with the new research.
This isn't the only study to link lifestyle to a delay in dementia.
Other research presented at the Alzheimer's Association conference Monday found that regular walking can protect the brains of people with a genetic risk for Alzheimer's.
The beauty of lifestyle interventions now proven to help keep cognition sharp is that they can be applied universally, said Rachel Wu, an associate professor of psychology who researches cognition in older adults at the University of California, Riverside.
'There's no downside, no side effects to doing this stuff, except just the time it takes,' Wu said.
POINTER trial researchers also took blood samples and scanned participants' brains, looking for amyloid and tau, proteins associated with Alzheimer's disease that form plaques and tangles in the brain.
Those samples will be included in a future analysis of study participants, said Heather Snyder, a POINTER researcher and senior vice president of medical and scientific relations at the Alzheimer's Association.
'If you have this biology, do you see a better response? Less response?' she said. 'That's the kind of meaningful question we're going to be able to ask with this data.' Additional findings are expected within the year, Snyder said.
Jones is eager to see those results when they're available.
'I don't know what they saw in my brain, but I know I'm a different person,' Jones said. She's lost 30 pounds and is no longer considered prediabetic or a candidate for statins to reduce her cholesterol.
'I'm going to keep moving, eating right, socializing, monitoring my comorbidities,' she said. 'I'm going to take care of myself.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
6 hours ago
- Associated Press
Biomed Industries Presents Four Breakthrough Studies on Alzheimer's, Rett Syndrome, and Obesity Therapies at AAIC 2025
Biomed Industries, Inc. Presents Four Pivotal Studies at AAIC 2025 Highlighting Breakthrough Therapies for Alzheimer's, Rett Syndrome, and Obesity 'NA-831 is the only drug to date that has halted Alzheimer's disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.'— Dr. Lloyd L. Tran, CEO of Biomed SAN JOSE, CA, UNITED STATES, August 4, 2025 / / -- Biomed Industries, Inc., a leading biopharmaceutical innovator developing transformative therapies for neurological and metabolic diseases, today announced the presentation of four major scientific papers at the Alzheimer's Association International Conference (AAIC), held July 27–31, 2025, in Toronto, Canada. The presentations featured Biomed's next-generation oral therapies for Alzheimer's disease, Rett syndrome, and obesity, with a focus on novel combination strategies designed to enhance safety, efficacy, and accessibility. Featured AAIC 2025 Presentations: 1. The End of the Amyloid Era? Evidence for a Paradigm Shift in the Quest to Treat Alzheimer's Disease 2. A Phase 3 Clinical Protocol of NA-831 Combined with Donanemab in Early Alzheimer's Disease: A Placebo-Controlled, Double-Blind Study 3. Associations Between Alzheimer's Disease and Rett Syndrome: Clinical Trials of NA-831 and NA-921 4. Neuro-Metabolic Link Between Alzheimer's Disease and Obesity: Clinical Evaluation of NA-831 and NA-931 1. PRESENTATION: The End of the Amyloid Era? A Paradigm Shift in Alzheimer's Research For over three decades, the 'amyloid hypothesis' has dominated Alzheimer's disease (AD) research, asserting that amyloid-β accumulation is a primary driver of neurodegeneration. Biomed's comprehensive analysis of Phase 3 trial data from seven anti-amyloid drugs — including aducanumab, lecanemab, donanemab, gantenerumab, bapineuzumab, crenezumab, and solanezumab — challenges this paradigm. Across all trials, both treatment and placebo groups exhibited similar cognitive decline, as measured by CDR-SB and ADAS-Cog. The average differences between treatment and placebo arms were minor and not clinically significant (CDR-SB: -0.25; ADAS-Cog: -0.79). Slope comparisons further revealed near-identical rates of decline between groups. 'Our analysis of Phase 3 clinical trial data for seven anti-amyloid drugs, including FDA-approved Aducanumab, Lecanemab, and Donanemab, indicates that none could halt disease progression in a clinically meaningful way — and all carried serious safety concerns,' said Dr. Zung Tran, VP of Biostatistics and AI at Biomed. 2. PRESENTATION: Phase 3 Clinical Protocol of NA-831 Combined with Donanemab NA-831, Biomed's lead oral candidate, is a first-in-class therapy that promotes neuroprotection, neurogenesis, and memory enhancement. Phase 2 trials demonstrated its disease-modifying potential with a favorable safety profile compared to traditional anti-amyloid drugs. In this upcoming Phase 3 study, NA-831 will be evaluated in combination with Donanemab, a recently FDA-approved monoclonal antibody, to explore synergistic effects. The goal is to lower Donanemab dosing, thereby reducing risks such as cerebral edema and microbleeds, while enhancing cognitive outcomes. 'NA-831 is the only drug to date that has halted disease progression in Phase 2 trials,' said Dr. Lloyd Tran, CEO of Biomed Industries. 'Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.' 3. PRESENTATION: Alzheimer's and Rett Syndrome: Shared Mechanisms and Dual Therapeutic Potential Biomed also presented findings on NA-921, a structural analog of NA-831 developed for Rett syndrome, a rare X-linked neurodevelopmental disorder. NA-921 modulates MeCP2 expression, targeting the disorder's core epigenetic dysfunction. A double-blind, placebo-controlled Phase 2/3 trial ( ID: NCT06849973) demonstrated promising results: Clinical Global Impression–Improvement (CGI-I) at week 12: NA-921: 3.60 | Placebo: 3.83 | P = 0.0020 | Effect size = 0.42 NA-921 was well tolerated, with a significantly improved safety profile compared to trofinetide: - Diarrhea: Trofinetide 82%, NA-921 24%, Placebo 19% - Vomiting: Trofinetide 29%, NA-921 9%, Placebo 11% - Fever: Trofinetide 9%, NA-921 5%, Placebo 4% These findings underscore a possible biological link between Alzheimer's disease and Rett syndrome, opening new cross-indication opportunities for NA-831 and NA-921. 4. PRESENTATION: Neuro-Metabolic Connections: NA-831 and NA-931 in Alzheimer's and Obesity Biomed's data also revealed compelling evidence of a neuro-metabolic bridge between Alzheimer's disease, diabetes, and obesity. In addition to NA-831's CNS benefits, Biomed is advancing NA-931, an oral quadruple receptor agonist (IGF-1, GLP-1, GIP, and glucagon) designed to treat obesity. In a 13-week Multiple Ascending Dose (MAD) study: - Mean body weight reduction: Up to 13.8% at 150 mg daily, 12.4% greater than placebo - ≥12% weight loss achieved by 72% of NA-931-treated patients vs. 2% in placebo group NA-931 demonstrated a strong safety profile, with mild and transient GI-related adverse events, and no observed muscle loss. 'Our pipeline shows how targeting interconnected pathways across the CNS and metabolic systems can unlock significant clinical potential,' said Michael Willis, VP of Business Development. 'With six active programs across Alzheimer's, ALS, Rett syndrome, stroke, obesity, and MASH, we are building a diversified platform to accelerate innovation and value creation.' ABOUT BIOMED INDUSTRIES, INC. Biomed Industries, Inc. is a pioneering biopharmaceutical company committed to developing novel therapeutics that address unmet medical needs. Its innovative research platform has produced treatments for conditions including Alzheimer's disease, ALS, Traumatic Brain Injury, Major Depressive Disorder, Diabetes, Obesity, MASH, Stroke, and rare diseases such as Huntington Disease and Rett Syndrome. (Website: ) Michael Willis Biomed Industries, Inc. email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Bloomberg
a day ago
- Bloomberg
Healthy Living Helps the Aging Brain
A new study published in the Journal of the American Medical Association makes a compelling case that a healthy lifestyle does an aging brain good. That might sound obvious. Eat well, exercise, challenge yourself mentally, have an active social life and you'll be better off for it. Yet researchers are just starting to offer concrete data to support the theory that making conscientious lifestyle changes can lower the risk of dementia, which is estimated to affect some 6 million Americans.


New York Post
2 days ago
- New York Post
‘Horny' mom, 42, reveals terrifying reason behind the sudden loss of her sex drive: ‘My partner took it personally'
A British mom says she was stunned to learn what was behind the sudden loss of her sex drive. Leanne Jones, 42, was once 'horny,' admitting she loved spending hours in the bedroom with partner Adam, 40. Several years ago, the former legal secretary suddenly found herself struggling to get aroused and wasn't able to climax as usual. 'I went from being very highly sex driven to feeling like Grandpa Joe from 'Willy Wonka,'' the mom-of-two, from South Wales in the United Kingdom, told Jam Press. 5 'I went from being very highly sex driven to feeling like Grandpa Joe from Willy Wonka,' the mom-of-two, from South Wales in the United Kingdom, told Jam Press. Jam Press/@leanne_fighting_ms 5 'There have been many times my partner could've walked away, but he says we are a team,' Jones said. She is pictured with Adam. Jam Press/@leanne_fighting_ms 'My partner took it personally at first, as many would, and thought I didn't love him anymore,' she continued. 'No matter how hard I tried, I couldn't get back my once horny self.' Jones was also experiencing 'crippling' fatigue and partial hearing loss. Knowing something wasn't quite right, she saw her doctor and was booked in for an MRI scan. Shockingly, the Brit was diagnosed with two conditions; Multiple Sclerosis (MS), which affects the brain and spinal cord, and functional neurological disorder, which impacts how the brain receives and sends information to the rest of the body. 'Because of the nerve damage to the brain and spine, the signals needed for arousal, sensation and orgasm are no longer there,' Jones explained. 'It creates a disconnect. For us women, there's issues with low sex drive, lack of sensation and lubrication and pain.' 5 'Because of the nerve damage to the brain and spine, the signals needed for arousal, sensation and orgasm are no longer there,' Jones explained. Jam Press/@leanne_fighting_ms 5 The Brit was diagnosed with two conditions; multiple sclerosis, which affects the brain and spinal cord, and functional neurological disorder, which impacts how the brain receives and sends information to the rest of the body. Jam Press/@leanne_fighting_ms While Jones' partner was initially upset about lack of interest in sex, he is standing by her as she faces her health battle. 'There have been many times my partner could've walked away, but he says we are a team,' Jones stated.'I spoke with an MS neurologist in front of him about the issues we were having in the bedroom and he understood that it's not him, it's my brain.' Jones is now an advocate for other people who are suffering MS, taking to TikTok to explain how the illness impacts sex drive. 'I had a number of male sufferers message to thank me for discussing it as a few of them had lost partners over it,' the mom told Jam Press. 'This is why it's so important to raise awareness. It's such a debilitating and lonely life.' 5 In addition to her lack of sex drive, Jones is suffering from problems with her speech and issues with her mobility and vision. Jam Press/@leanne_fighting_ms In addition to her lack of sex drive, Jones is suffering from problems with her speech and issues with her mobility and vision. However, the mom insists she's still able to enjoy her life. 'I want people to know that even though it feels like a prison sentence, it's not,' she said. 'You've got to work with it, not against it, as there's so much to live for.'